PDCD1 and neoplasm: CD8-p53KO mice had intact tumor control and improved survival with APR-246 plus anti–PD-1, indicating that loss of p53 in T cells did not abrogate the therapeutic effect associated with a systemic increase in p53 expression (Figure 3F).